Glutathione S-transferase omega-1
AltitudeomicsDB
Protein Official symbol |
GSTO1 |
Aliases |
GSTO1 GSTTLP28 |
Chromosomal Location |
10 |
Length |
241 |
Uniprot ID |
P78417 |
EC number |
2.5.1.18; 1.8.5.1; 1.20.4.2 |
Protein family Information(Pfam) |
PF14497;PF13417; |
PDB id |
1EEM;3LFL;3VLN;4IS0;4YQM;4YQU;4YQV;5UEH;5V3Q;5YVN;5YVO;6MHB;6MHC;6MHD;6PNM;6PNN;6PNO; |
InterPro ID |
IPR010987;IPR036282;IPR004045;IPR004046;IPR005442;IPR036249; |
dbSNP |
rs45529437 rs11509436 rs4925 rs11509438 rs11509439 |
AltitudeomicsDB
Protein 1 |
Protein 2 |
Combine Score |
STAT4 |
GSTO1 |
0.9 |
Association with High Altitude
Protein Official symbol |
Source Organism |
Tissue of Expression |
Level of hypoxia |
Altitude |
Duration of experiment |
Level of expression |
Fold change |
Experiment details |
geographical location |
ethnicity of the patients |
Control group |
Control (Fold change) |
Reference (PMID) |
GSTO1 |
Human |
Skeletal muscle |
- |
4559 m |
9 day |
downregulated |
-1.34 |
2-DIGE |
Southern Europe |
Italians |
1 |
Fasting control subjects at laboratory in Copenhagen with no caffeine intake |
18937252 |
GSTO1 |
Human |
Blood |
- |
3600 m |
Native |
upregulated |
- |
TMT-based proteomic analysis/LC-MS |
Central Asia |
Tibetans |
- |
High altitude native vs. low Lander |
30908922 |
Gene Ontology
ID |
GO ID |
GO Term |
GO Type |
9446 |
GO:0019852 |
L-ascorbic acid metabolic process |
GOTERM_BP_DIRECT |
9446 |
GO:0006749 |
glutathione metabolic process |
GOTERM_BP_DIRECT |
9446 |
GO:0010880 |
regulation of release of sequestered calcium ion into cytosol by sarcoplasmic reticulum |
GOTERM_BP_DIRECT |
9446 |
GO:0014810 |
positive regulation of skeletal muscle contraction by regulation of release of sequestered calcium ion |
GOTERM_BP_DIRECT |
9446 |
GO:0004364 |
glutathione transferase activity |
GOTERM_MF_DIRECT |
9446 |
GO:0060316 |
positive regulation of ryanodine-sensitive calcium-release channel activity |
GOTERM_BP_DIRECT |
9446 |
GO:0050610 |
tau-protein kinase activity |
GOTERM_MF_DIRECT |
9446 |
GO:0016491 |
oxidoreductase activity |
GOTERM_MF_DIRECT |
9446 |
GO:0045174 |
poly |
GOTERM_MF_DIRECT |
9446 |
GO:0098869 |
cellular oxidant detoxification |
GOTERM_BP_DIRECT |
9446 |
GO:0070062 |
extracellular exosome |
GOTERM_CC_DIRECT |
9446 |
GO:0060315 |
negative regulation of ryanodine-sensitive calcium-release channel activity |
GOTERM_BP_DIRECT |
9446 |
GO:0008152 |
metabolic process |
GOTERM_BP_DIRECT |
9446 |
GO:0055114 |
oxidation-reduction process |
GOTERM_BP_DIRECT |
9446 |
GO:0042178 |
xenobiotic catabolic process |
GOTERM_BP_DIRECT |
9446 |
GO:0032259 |
methylation |
GOTERM_BP_DIRECT |
9446 |
GO:1901687 |
glutathione derivative biosynthetic process |
GOTERM_BP_DIRECT |
9446 |
GO:0005515 |
protein binding |
GOTERM_MF_DIRECT |
9446 |
GO:0005737 |
cytoplasm |
GOTERM_CC_DIRECT |
9446 |
GO:0005829 |
cytosol |
GOTERM_CC_DIRECT |
9446 |
GO:0010881 |
regulation of cardiac muscle contraction by regulation of the release of sequestered calcium ion |
GOTERM_BP_DIRECT |
9446 |
GO:0071243 |
cellular response to arsenic-containing substance |
GOTERM_BP_DIRECT |
Pathways
Human Entrez ID |
KEGG ID |
KEGG Term |
9446 |
hsa00480 |
Glutathione metabolism |
9446 |
hsa00980 |
Metabolism of xenobiotics by cytochrome P450 |
9446 |
hsa00982 |
Drug metabolism - cytochrome P450 |
9446 |
hsa05204 |
Chemical carcinogenesis |
Association with Disease
Protein Official Symbol |
Human Entrez ID |
Disease Name |
Disease Id |
Disease Semantic Type |
Semantic score |
DSI |
DPI |
Disease Type |
GSTO1 |
9446 |
leukemia |
C0023418 |
Neoplastic Process |
0.3 |
0.627 |
0.552 |
disease |
GSTO1 |
9446 |
Malignant Neoplasms |
C0006826 |
Neoplastic Process |
0.3 |
0.627 |
0.552 |
group |
GSTO1 |
9446 |
Neoplasms |
C0027651 |
Neoplastic Process |
0.3 |
0.627 |
0.552 |
group |
GSTO1 |
9446 |
Neurodegenerative Disorders |
C0524851 |
Disease or Syndrome |
0.31 |
0.627 |
0.552 |
group |
GSTO1 |
9446 |
Lung diseases |
C0024115 |
Disease or Syndrome |
0.31 |
0.627 |
0.552 |
group |
GSTO1 |
9446 |
Benign Neoplasm |
C0086692 |
Neoplastic Process |
0.3 |
0.627 |
0.552 |
group |
GSTO1 |
9446 |
Dermatologic disorders |
C0037274 |
Disease or Syndrome |
0.3 |
0.627 |
0.552 |
group |
GSTO1 |
9446 |
Squamous cell carcinoma of esophagus |
C0279626 |
Neoplastic Process |
0.3 |
0.627 |
0.552 |
disease |
GSTO1 |
9446 |
Degenerative Diseases, Spinal Cord |
C0751733 |
Disease or Syndrome |
0.3 |
0.627 |
0.552 |
disease |
GSTO1 |
9446 |
Precancerous Conditions |
C0032927 |
Neoplastic Process |
0.3 |
0.627 |
0.552 |
group |
GSTO1 |
9446 |
Condition, Preneoplastic |
C0282313 |
Neoplastic Process |
0.3 |
0.627 |
0.552 |
phenotype |
GSTO1 |
9446 |
Malignant neoplasm of prostate |
C0376358 |
Neoplastic Process |
0.3 |
0.627 |
0.552 |
disease |
GSTO1 |
9446 |
Prostatic Neoplasms |
C0033578 |
Neoplastic Process |
0.3 |
0.627 |
0.552 |
group |
GSTO1 |
9446 |
Degenerative Diseases, Central Nervous System |
C0270715 |
Disease or Syndrome |
0.3 |
0.627 |
0.552 |
group |
Association with Drug
Protein Official Symbol |
Human Entrez ID |
drug_claim_primary_name |
drug_name |
drug_chembl_id |
interaction_types |
GSTO1 |
9446 |
ARSENIC TRIOXIDE |
ARSENIC TRIOXIDE |
CHEMBL1200978 |
None |